Shanghai Tangrun Pharmaceutical

Tangrun Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative metabolic therapies. The company focuses on the discovery and clinical advancement of small molecule agonists targeting the GLP-1, GIP, and Glucagon receptors for the treatment of metabolic disorders such as type 2 diabetes and obesity. Its lead candidate, TRM-201, is an oral small molecule GLP-1 receptor agonist designed to provide a more convenient alternative to injectable treatments. Tangrun aims to address the growing global burden of metabolic diseases through high-quality, accessible pharmaceutical innovation.